Oncology M&A: Achieving Better Outcomes?

Posted by Arup Das on Jun 4, 2019 8:00:00 AM

Pranav Srivastava co-wrote this blog post with Arup Das.

Merger and acquisition (M&A) activity for the oncology, pharma and biotech sector is off to a blistering start in 2019. Three huge deals announced in the first two months of the year have set the pace for what could be a record-breaking year: 


>
Read More

Five Key Insights From Oncology First Launches

Posted by Ben Hohn on May 31, 2019 9:27:29 AM

Judith Kulich, Jon Roffman, Cody Powers and Renuka Agarwal co-wrote this blog post with Ben Hohn.

Oncology continues to be the leading therapeutic area for first launches by emerging biopharma companies in the United States. Recent ZS analysis identified 125 U.S. biopharma companies with first launches from 2011 to 2018, and 51 of those were for novel drugs. Of these 51,14 were in oncology—the largest number of any therapeutic area.


>
Read More

Payers’ Hands Are Still Tied With Oncology Combination Regimens

Posted by Nicolle Hamilton on May 23, 2019 10:11:35 AM

Lawrence Lee co-wrote this blog post with Nicolle Hamilton.  

The oncology pipeline is rich with potential combination regimens across both liquid and solid tumor types. Several manufacturers are developing or marketing PD-1/PD-L1 checkpoint inhibitors as a “backbone” for their combination regimen portfolio. Although there are only a few currently marketed regimens with multiple targeted agents (such as Opdivo-Yervoy in ovarian cancer, Tafinlar-Mekinist in metastatic melanoma, and several combos in multiple myeloma), combination approaches may become the standard of care for many tumor types. Indeed, these novel-novel approaches can yield compelling clinical outcomes. For example, Opdivo-Yervoy reduced progression risk by 58% vs. Yervoy alone in melanoma.


>
Read More

Smarter, Faster, Better: Leveraging Artificial Intelligence in Oncology Market Research

Posted by Sonal Singh on Feb 28, 2019 1:27:59 PM

Aritra Das co-authored this blog post with Sonal Singh. 

The oncology market has become increasingly crowded and complex incredibly quickly. As an oncology market researcher, you might be feeling a lot of pressure to up the analytical sophistication in your research and capture nuanced decision-making, all while getting insights to your key stakeholders faster. Have you ever wondered how AI could help solve some of the burning challenges that you’re facing, and help you get robust answers to your questions quickly to help you keep up with the rapidly changing market? Here’s how AI can help.


>
Read More

AI Is Driving Change in Oncology Practice and Commercialization. Are You Part of the Wave?

Posted by Shankar Viswanathan on Feb 15, 2018 9:15:07 AM

Arup Das co-wrote this blog post with Shankar Viswanathan.

Looking back at 2017, artificial intelligence and machine learning made impressive progress when it comes to improving cancer diagnosis and treatment. Using deep learning, computers are scouring images to detect signs of breast cancer in mammograms earlier than humans are currently capable of. Using AI “random forests,” a learning algorithm, investigators are more accurately predicting which drug combination will work better in BRAF mutant melanoma. The AI-facilitated discovery of Berg Health’s BPM 31510, a pancreatic cancer drug, has entered human development clinical trials. AI is not only powering oncology drug discovery, faster detection and personalized treatment but also helping to improve oncology commercialization effectiveness and agility through analytics. 


>
Read More